Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer

10.4077/CJP.2012.BAA075

Chen-Chin Pen；Che-Ming Liu；Cho-Chin Lin；Chia-Chen Lin；Teng-Fu Hsieh；Sajni Josson；Yun-Chi He；Leland W. K. Chung；Keh-Liang Lin；Shian-Ying Sung

ADAM9 ； prostate cancer ； urine VEGF

The Chinese Journal of Physiology

55卷6期（2012 / 12 / 31）

390 - 397

英文

Recent evidence has demonstrated that detection of changes in the levels of urinary vascular endothelial growth factor (VEGF) and tissue a disintegrin and metalloproteinase 9 (ADAM9) is effective in determining prostate cancer progression. To evaluate the combined application of VEGF and ADAM9 as early progression markers of lethal phenotypic cancer, quantification of urinary VEGF and tissue ADAM9 expression was studied in patients with late stage prostate cancer. Tissue biopsies were collected during palliative transurethral resection of prostate (TURP) surgery, and urine samples were collected before hormone therapy and 3, 6 and 12 months post-TURP. We observed a nearly 100% correlation between increasing urinary VEGF levels over time and prostate cancer progression, but no correlation was observed when comparing urinary VEGF concentrations at a single time point and cancer progression. In addition, we also observed correlation of increasing ADAM9 nuclear positive staining and lethal phenotypic transition. Statistical analysis revealed that both the increase in urinary VEGF level and the presence of the tissue ADAM9 nuclear staining were significantly correlated with the risk of patients with relapse prostate cancer (P ＜ 0.05). Thus, we suggest that combination of detection of changes in urinary VEGF and tissue staining of ADAM9 may be accurate for predicting the mortality of patients with prostate cancer during hormone therapy.

1. Lin, C.K.,Jin, J.S.,Yu, C.P.,Tsai, W.C.(2011).Expression of LGR8 and related biomarkers in hepatocellular carcinoma: correlation with clinicopathological parameters.Chinese J. Physiol.,54,161-168.
   連結：
2. Tsai, J.Y.,Shieh, P.,Kuo, D.H.,Chen, F.A.,Kuo, C.C.,Jan, C.R.(2010).Effect of m-3M3FBS on Ca2+ movement in PC3 human prostate cancer cells.Chinese J. Physiol.,53,151-159.
   連結：
3. Bok, R.A.,Halabi, S.,Fei, D.T.,Rodriquez, C.R.,Hayes, D.F.,Vogelzang, N.J.,Kantoff, P.,Shuman, M.A.,Small, E.J.(2001).Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.Cancer Res.,61,2533-2536.
4. Boure, T.,Vanholder, R.(2004).Biochemical and clinical evidence for uremic toxicity.Artif. Organs,28,248-253.
5. Chan, L.W.,Moses, M.A.,Goley, E.,Sproull, M.,Muanza, T.,Coleman, C.N.,Figg, W.D.,Albert, P.S.,Menard, C.,Camphausen, K.(2004).Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.J. Clin. Oncol.,22,499-506.
6. Chung, L.W.,Hsieh, C.L.,Law, A.,Sung, S.Y.,Gardner, T.A.,Egawa, M.,Matsubara, S.,Zhau, H.E.(2003).New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions.Urology,62,44-54.
7. Edirisinghe, I.,Rahman, I.(2010).Cigarette smoke-mediated oxidative stress, shear stress, and endothelial dysfunction: role of VEGFR2.Ann. N. Y. Acad. Sci.,1203,66-72.
8. Fischer, O.M.,Hart, S.,Gschwind, A.,Prenzel, N.,Ullrich, A.(2004).Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor.Mol. Cell Biol.,24,5172-5183.
9. Fritzsche, F.R.,Jung, M.,Tolle, A.,Wild, P.,Hartmann, A.,Wassermann, K.,Rabien, A.,Lein, M.,Dietel, M.,Pilarsky, C.,Calvano, D.,Grutzmann, R.,Jung, K.,Kristiansen, G.(2008).ADAM9 expression is a significant and I ndependent prognostic marker of PSA relapse in prostate cancer.Eur. Urol.,54,1097-1108.
10. Gustavsson, H.,Welen, K.,Damber, J.E.(2005).Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.Prostate,62,364-373.
11. Hill, P.,Marquardt, H.(1980).Plasma and urine changes after smoking different brands of cigarettes.Clin. Pharmacol. Ther.,27,652-658.
12. Jackson, M.W.,Roberts, J.S.,Heckford, S.E.,Ricciardelli, C.,Stahl, J.,Choong, C.,Horsfall, D.J.,Tilley, W.D.(2002).A potential autocrine role for vascular endothelial growth factor in prostate cancer.Cancer Res.,62,854-859.
13. Jones, A.,Fujiyama, C.,Turner, K.,Fuggle, S.,Cranston, D.,Bicknell, R.,Harris, A.L.(2000).Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.BJU Int.,85,276-280.
14. Joseph, I.B.,Nelson, J.B.,Denmeade, S.R.,Isaacs, J.T.(1997).Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.Clin. Cancer Res.,3,2507-2511.
15. Josson, S.,Anderson, C.S.,Sung, S.Y.,Johnstone, P.A.,Kubo, H.,Hsieh, C.L.,Arnold, R.,Gururajan, M.,Yates, C.,Chung, L.W.(2011).Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.Prostate,71,232-240.
16. Kaygusuz, G.,Tulunay, O.,Baltaci, S.,Gogus, O.(2007).Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.Int. Urol. Nephrol.,39,841-850.
17. Korivi, M.,Hou, C.W.,Chen, C.Y.,Lee, J.P.,Kesireddy, S.R.,Kuo, C.H.(2010).Angiogenesis: Role of exercise training and aging.Adapt. Med.,2,29-41.
18. Mazzucchelli, R.,Montironi, R.,Santinelli, A.,Lucarini, G.,Pugnaloni, A.,Biagini, G.(2000).Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.Prostate,45,72-79.
19. Miyake, H.,Muramaki, M.,Kurahashi, T.,Yamanaka, K.,Hara, I.(2005).Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.Anticancer Res.,25,3645-3649.
20. Neufeld, G.,Cohen, T.,Gengrinovitch, S.,Poltorak, Z.(1999).Vascular endothelial growth factor (VEGF) and its receptors.FASEB J.,13,9-22.
21. Peduto, L.(2009).ADAM9 as a potential target molecule in cancer.Curr. Pharm. Des.,15,2282-2287.
22. Shigemura, K.,Sung, S.Y.,Kubo, H.,Arnold, R.S.,Fujisawa, M.,Gotoh, A.,Zhau, H.E.,Chung, L.W.(2007).Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.Prostate,67,722-731.
23. Sung, S.Y.,Hsieh, C.L.,Law, A.,Zhau, H.E.,Pathak, S.,Multani, A.S.,Lim, S.,Coleman, I.M.,Wu, L.C.,Figg, W.D.,Dahut, W.L.,Nelson, P.,Lee, J.K.,Amin, M.B.,Lyles, R.,Johnstone, P.A.,Marshall, F.F.,Chung, L.W.(2008).Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.Cancer Res.,68,9996-10003.
24. Sung, S.Y.,Hsieh, C.L.,Wu, D.,Chung, L.W.,Johnstone, P.A.(2007).Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance.Curr. Probl. Cancer,31,36-100.
25. Sung, S.Y.,Kubo, H.,Shigemura, K.,Arnold, R.S.,Logani, S.,Wang, R.,Konaka, H.,Nakagawa, M.,Mousses, S.,Amin, M.,Anderson, C.,Johnstone, P.,Petros, J.A.,Marshall, F.F.,Zhau, H.E.,Chung, L.W.(2006).Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.Cancer Res.,66,9519-9526.
26. Wade, T.P.,Kozlowski, P.(2007).Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors.Neoplasia,9,563-568.

1. Wu, Hsi-Chin,Tsai, Fu-Jenn,Tsai, Chang-Hai,Ting, Wei-Jen,Lin, Tien-Huang,Lee, Shang-Seu,Kuo, Sheng-Chu,Huang, Chih-Yang,Chien, Wen-Shin,Chen, Wen-Chi(2014).Induction of Apoptosis in Human DU145 Prostate Cancer Cells by KHC-4 Treatment.中國生理學雜誌,57(2),99-104.